Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by:
Fudan University
ClinicalTrials.gov Identifier:
NCT00524849
First received: September 4, 2007
Last updated: September 13, 2010
Last verified: September 2010